Navigation Links
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Date:1/25/2010

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm

QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals ( KERX), presented updated results yesterday on the clinical activity of perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda(R)) as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, "Randomized Phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results", was presented yesterday in a poster during the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in Orlando, Florida. Keryx is Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while Æterna Zentaris retains rights for the rest of the world.

Study Design

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colon cancer were randomized to receive cape
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... PXS, Nasdaq: PXSL) today announced that its Phase ... people with bronchiectasis has met its two,primary efficacy ... Data from the 362 subject study demonstrated a ... weeks of treatment with Bronchitol,as assessed by the ...
... SOMERSET, N.J., Aug. 28 DOV Pharmaceutical,Inc. ("DOV" or ... today that its common stock is now being quoted ... common stock is also still,being quoted on the Pink ... common stock are now being quoted,both on the OTC ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board 2
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... of mesenchymal stem cells can stimulate neurogenesis in the ... disease (AD) and improve tissue and function injury under ... on the therapeutic effect of adipose-derived stem cells (ADSCs) ... on oxidative injury and neurogenesis in the brain of ... of Life Sciences, Tsinghua University, China transplanted ADSCs into ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... BGI, the world,s largest genomic organization, today announced its ... of RNA-Seq in predicting patient outcomes as part of ... U.S. Food and Drug Administration (FDA). The SEQC, also ... MicroArray Quality Control (MAQC), aimed at assessing the technical ...
... upper and lower abdomen is a reliable, minimally invasive way ... indicator of too much male hormone, researchers report. "We ... women that was as non-intrusive and accurate as possible," said ... Sciences University. "We believe this approach is approximately ...
... controlled by the brain from blood pressure to appetite to ... , a team of scientists led by Dr. Gil Levkowitz of ... brain area in which biochemical commands are passed from the brain ... the process, they discovered a surprising new role for the ,hormone ...
Cached Biology News:BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq 2Women's chin, abdomen are good indicators of excessive hair growth 2Women's chin, abdomen are good indicators of excessive hair growth 3A hormone ensures its future 2
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: